Smart lipid-based nanosystems for therapeutic immune induction against cancers: Perspectives and outlooks

22Citations
Citations of this article
37Readers
Mendeley users who have this article in their library.

Abstract

Cancer immunotherapy, a promising and widely applied mode of oncotherapy, makes use of immune stimulants and modulators to overcome the immune dysregulation present in cancer, and leverage the host’s immune capacity to eliminate tumors. Although some success has been seen in this field, toxicity and weak immune induction remain challenges. Liposomal nanosystems, previously used as targeting agents, are increasingly functioning as immunotherapeutic vehicles, with potential for delivery of contents, immune induction, and synergistic drug packaging. These systems are tailorable, multifunctional, and smart. Liposomes may deliver various immune reagents including cytokines, specific T-cell receptors, antibody fragments, and immune checkpoint inhibitors, and also present a promising platform upon which personalized medicine approaches can be built, especially with preclinical and clinical potentials of liposomes often being frustrated by inter-and intrapatient variation. In this review, we show the potential of liposomes in cancer immunotherapy, as well as the methods for synthesis and in vivo progression thereof. Both preclinical and clinical studies are included to comprehensively illuminate prospects and challenges for future research and application.

Cite

CITATION STYLE

APA

Fobian, S. F., Cheng, Z., & Ten Hagen, T. L. M. (2022, January 1). Smart lipid-based nanosystems for therapeutic immune induction against cancers: Perspectives and outlooks. Pharmaceutics. MDPI. https://doi.org/10.3390/pharmaceutics14010026

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free